1,2,3-Triazole hybrids as anticancer agents: A review

Arch Pharm (Weinheim). 2022 Jan;355(1):e2100158. doi: 10.1002/ardp.202100158. Epub 2021 Sep 24.

Abstract

Despite the advancements in the development of anticancer agents, more effective and safer anticancer drugs still need to be developed as the current agents cause unwanted side effects and many patients have become drug resistant. 1,2,3-Triazoles, due to their remarkable biological potential, have received considerable attention in drug discovery for the development of anticancer agents. The present review article presents an overview of the recent advances in 1,2,3-triazole hybrids with anticancer potential over the last 2 years, their chemical structures, structure-activity relationships, and mechanisms of action, as well as insights into the docking studies.

Keywords: 1,2,3-triazole; cancer; mechanism of action; structure-activity relationship.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Drug Development
  • Drug Discovery
  • Humans
  • Neoplasms / drug therapy*
  • Structure-Activity Relationship
  • Triazoles / adverse effects
  • Triazoles / chemistry
  • Triazoles / pharmacology*

Substances

  • Antineoplastic Agents
  • Triazoles